Abstract
Background: Inclusion of anticancer drugs into biocompatible nanoparticulate carriers decreases the general toxicity and improves the efficacy of clinical treatments due to the reduction of soluble circulating free drugs.
Methods: In addition, removal of emerging drug contaminants from wastewaters is a necessity that should be seriously attended. Boron nitride (BN) is a choice in drug delivery because of its many surprising properties. Here, boron nitride nanoparticles are prepared, characterized by Fourier-transform infrared spectroscopy (FT-IR) and x-ray diffraction (XRD) and used in the delivery of melphalan anti-cancer drug.
Results: Then, density functional theory (DFT) calculations are carried out to study the adsorption of this drug on the surface of pure boron nitride fullerene via familiar hybrid functionals B3LYP and B3PW91. In addition, the polarizable continuum model (PCM) calculations show that BN is stable in water.
Conclusion: Finally, the in vitro cellular toxicity and viability of BN nanoparticles was examined on ES-2 cancer cells. The inhibitory dose IC50 of the material confirmed acceptable cytotoxicity and nanoparticles affected the average growth of the ES-2 cancer cells.
Keywords: Melphalan, adsorption, DFT method, boron nitride fullerene, anti-ovarian cancer drug, PCM.
Current Molecular Medicine
Title:Studying Adsorption and Cellular Toxicity of Boron Nitride Nanostructure versus Melphalan Anti-ovarian Cancer Drug
Volume: 21 Issue: 8
Author(s): Min Fu, Reza Tayebee*, Satar Saberi, Narjes Nourbakhsh, Effat Esmaeili, Behrooz Maleki and Hamid R. Vatanpour
Affiliation:
- Department of Chemistry, School of Sciences, Hakim Sabzevari University, Sabzevar, 96179-76487,Iran
Keywords: Melphalan, adsorption, DFT method, boron nitride fullerene, anti-ovarian cancer drug, PCM.
Abstract:
Background: Inclusion of anticancer drugs into biocompatible nanoparticulate carriers decreases the general toxicity and improves the efficacy of clinical treatments due to the reduction of soluble circulating free drugs.
Methods: In addition, removal of emerging drug contaminants from wastewaters is a necessity that should be seriously attended. Boron nitride (BN) is a choice in drug delivery because of its many surprising properties. Here, boron nitride nanoparticles are prepared, characterized by Fourier-transform infrared spectroscopy (FT-IR) and x-ray diffraction (XRD) and used in the delivery of melphalan anti-cancer drug.
Results: Then, density functional theory (DFT) calculations are carried out to study the adsorption of this drug on the surface of pure boron nitride fullerene via familiar hybrid functionals B3LYP and B3PW91. In addition, the polarizable continuum model (PCM) calculations show that BN is stable in water.
Conclusion: Finally, the in vitro cellular toxicity and viability of BN nanoparticles was examined on ES-2 cancer cells. The inhibitory dose IC50 of the material confirmed acceptable cytotoxicity and nanoparticles affected the average growth of the ES-2 cancer cells.
Export Options
About this article
Cite this article as:
Fu Min , Tayebee Reza *, Saberi Satar , Nourbakhsh Narjes , Esmaeili Effat , Maleki Behrooz and Vatanpour R. Hamid , Studying Adsorption and Cellular Toxicity of Boron Nitride Nanostructure versus Melphalan Anti-ovarian Cancer Drug, Current Molecular Medicine 2021; 21 (8) . https://dx.doi.org/10.2174/1566524021666210111104428
DOI https://dx.doi.org/10.2174/1566524021666210111104428 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Strategies for Conjugation of Biomolecules to Nanoparticles as Tumor Targeting Agents
Current Pharmaceutical Design Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Biological Evidence for the Benefit of Green Tea and EGCG in Arthritis
Current Rheumatology Reviews Role of Caspases, Bax and Bcl-2 in Chrysin-Induced Apoptosis in the A549 Human Lung Adenocarcinoma Epithelial Cells
Anti-Cancer Agents in Medicinal Chemistry Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the Immune- System Related Risk Factors
Current Pharmaceutical Design Reconstruction, Topological and Gene Ontology Enrichment Analysis of Cancerous Gene Regulatory Network Modules
Current Bioinformatics Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Rapid Assays for Quantitating Cytokine Gene Expression Without Target Amplification
Combinatorial Chemistry & High Throughput Screening Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology Exploring the Molecular Mechanisms of 17β-HSD5-induced Carcinogenicity of <i>Catha edulis</i> via Molecular Modeling Approach
Medicinal Chemistry An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Genetic Profile of SNP(s) and Ovulation Induction
Current Pharmaceutical Biotechnology Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry The Epigenetic Origin of Aneuploidy
Current Genomics Parallel Solid-Phase Synthesis using a New Diethylsilylacetylenic Linker and Leading to Mestranol Derivatives with Potent Antiproliferative Activities on Multiple Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Patents in Cancer Stem Cells
Recent Patents on Biomarkers Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil
Clinical Cancer Drugs